Drug Profile

H5N1 influenza virus vaccine intranasal - National Resilience

Alternative Names: GelVac™ nasal influenza vaccine

Latest Information Update: 18 Jun 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator DelSite Biotechnologies
Developer National Resilience
Class Influenza A virus H5N1 vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Influenza virus infections

Most Recent Events

28 Apr 2018 No recent reports of development identified for phase-I development in Influenza-virus-infections in USA (Intranasal, Powder)
02 Oct 2017 Nanotherapeutics is now called as Ology Bioservices
20 Apr 2016 This programme is still active

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com